ESMO shared on LinkedIn:

“As Annals Of Oncology 35th Anniversary is commemorated, here are two top-cited 2023 papers:

‘Primary results from IMpassion131: Paclitaxel with or without atezolizumab for triple-negative breast cancer’

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Authors: D. Miles, J. Gligorov, F. André, D. Cameron, A. Schneeweiss, C. Barrios, B. Xu, A. Wardley, D. Kaen, L. Andrade, V. Semiglazov, M. Reinisch, S. Patel, M. Patre, L. Morales, S.L. Patel, M. Kaul, T. Barata, J. O’Shaughnessy

Annals Of Oncology

‘ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer’

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Authors: J. Pascual, G. Attard, F.-C. Bidard, G. Curigliano, L. De Mattos-Arruda, M. Diehn, A. Italiano, J. Lindberg, J.D. Merker, C. Montagut, N. Normanno, K. Pantel, G. Pentheroudakis, S. Popat, J.S. Reis-Filho, J. Tie, J. Seoane, N. Tarazona, T. Yoshino, N.C. Turner

Annals Of Oncology

Two top-cited 2023 papers on Annals Of Oncology – ESMO